Introduction
Malignant GBM is the most common and lethal brain tumor, however, current therapeutic options offer little prognostic improvement, and the median survival time has remained virtually unchanged for several decades (1) (2) (3) . GBM tumor mass is a heterogeneous mix of cells expressing lineage markers found in neural stem/precursor cells, neurons, and glia, and aberrantly expressed proliferation markers (4, 5) . TPCs are a subpopulation of GBM cells with increased tumorigenic capability (6) operationally defined as early passaged (<15) GBM cells propagated in serum-free medium (7) .
Compared to the bulk of the tumor, TPCs are more resistant to drugs, such as temozolomide (TMZ), and radiation therapy (8, 9) . This resistance may explain the failure of traditional therapeutic strategies based on cytotoxic drugs targeting GBM. A promising alternative approach aims to drive differentiation of tumor cells, particularly TPCs, thereby reducing tumor expansion through decreased cell proliferation and increasing sensitivity to cytotoxic treatments (10) (11) (12) (13) (14) (15) .
Culturing primary GBM cells in serum-containing medium induces their differentiation into cells with drastically reduced tumorigenic potential (16) . In addition, Bone Morphogenetic Protein 4 (BMP4) treatment was reported to induce GBM differentiation (17, 18) , which might be reversible (19) and is contingent on the presence of functional BMP receptors (20) . These observations support the potential therapeutic value of small molecules that mimic the differentiation effect of serum and BMPs on TPCs. Several studies successfully performed high content screenings using normal neural progenitor and monolayer cultures of GBM to identify cytotoxic molecules (21, 22) . However, attempts to design screening strategies identifying inducers of GBM differentiation have been met with multiple difficulties. One critical problem is the lack of informative markers for GBM differentiation. The most commonly used markers (e.g. sex-determining region Y-box 2 (SOX2) and glial fibrillary acidic protein (GFAP)), exhibit highly variable expression in TPCs (4) and in our hands these markers failed to prioritize molecules mimicking serum/BMP ability to differentiated GBM. In addition, recent single-cell expression analysis of primary GBM was unable to identify a limited set of GBM differentiation markers that could be used for high-throughput screening (23) .
Here, we introduce MIEL, a novel phenotypic screening platform that takes advantage of epigenetic modifications and multiparametric image analysis to reveal a signature of TPC differentiation amenable to high-content screening. We have validated MIEL's ability to select and prioritize small molecules mimicking serum/BMP4 effect on GBM using global gene expression profiling. This new approach opens the door for discovering small molecule drugs that can phenocopy the effect of biologicals such as serum or BMP known to induce GBM differentiation.
Results

Brief treatment with serum or Bmp4 initiates TPC differentiation.
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A comparative analysis of gene expression changes in TPCs following short serum or Bmp4 treatment, which is relevant to our high-throughput screening objective, has not been conducted. We therefore treated several GBM cell lines for 3 days with serum or Bmp4 and then quantified expression of core transcription factors previously shown to determine the transcriptomic program of TPCs (6) . Immunostaining revealed that the 4 transcription factors Sox2, Sall2, Brn2 and Olig2 were down regulated by both serum and Bmp4 in a cell line dependent manner ( Supplementary Fig. 1a ).
After 3 days of treatment, the growth rate of TPCs was reduced by both serum and Bmp4
( Supplementary Fig. 1b ). RNAseq analysis of serum and Bmp4 treated GBM2 cells revealed that 3 days treatment reduced (vs untreated cells) the expression of most genes previously found to constitute the transcriptomic stemness signature (23) (Supplementary Fig. 1c ). To identify the cellular processes altered by these treatments, we conducted differential expression analysis. We found that expression of 4852 genes was significantly altered (p<0.01 and -1.5<Fold Change >1.5) by either serum or Bmp4 treatment. Gene Ontology (GO) analysis of these altered genes indicated enrichment in multiple GO categories consistent with initiation of TPC differentiation -including cell cycle, cellular morphogenesis associated with differentiation, differentiation in neuronal lineages, histone modification, and chromatin organization ( Supplementary Fig. 2 ). Taken together, these results demonstrate that a 3 days treatment with serum or Bmp4 is sufficient to result in transcriptomic changes characteristic of TPC differentiation.
Sox2-and GFAP-based screening doesn't prioritize inducers of TPC differentiation.
Several studies suggest that Sox2 function is required for maintenance of TPCs and that its knockdown induces TPC differentiation (6, 15, 24, 25) . We therefore selected Sox2 as a marker of the TPC state. For the differentiated state, we selected GFAP, an astrocytic marker previously shown to be upregulated following differentiation of TPCs (6, 24) . We confirmed that Bmp4, but not serum, treatment also increased GFAP expression ( Supplementary Fig. 1a ).
Among several GBMs tested, the GBM2 line exhibited the largest reduction in Sox2 and increase in GFAP and was selected for screening. GBM2 TPCs were plated in 384-well plates, treated with the Prestwick library compounds (10 µM, 1200 molecules) for 3 days, fixed, and then immunostained for Sox2 and GFAP. Hits were defined as compounds that increased GFAP and decrease Sox2 by more than 40% or any compounds that decrease Sox2 alone by more than 100%;
Bmp4 was used as a positive control (Fig. 1a) . We detected 19 hits ( Supplementary Fig. 3 ), however, reduced cell viability and the presence of pyknotic nuclei indicated apparent cytotoxicity of the most hits (z-score for viable cell count less than -4 compared with -2.33 for Bmp4; Supplementary Fig. 3 ).
We therefore retested the hit compounds at lower concentrations (3, 1 and 0.3µM) and observed that a 3 days treatment with 0.3µM Digitoxigenin, a Na + /K + ATPase inhibitor, was able reduce Sox2 5 expression while maintaining growth rate and Ki67 expression levels similar to Bmp4 (Fig. 1b, c and supplementary Fig. 10a) . A related compound Digoxin also reduced Sox2 expression but induced a stronger reduction in growth rate (Fig. 1b, c (Fig. 1d) . Several representative GO terms illustrate the gene expression changes induced by digoxin and digitoxigenin which were markedly different from those induced by serum or BMP4 (Fig. 1e) . We concluded that our 2 top hits didn't induce desirable TPC fate change, despite downregulation of some core transcription factors essential for TPC propagation. Our results emphasize the need of developing novel approaches to interrogate TPC differentiation, which are compatible with the high-throughput screening and align well with the entire transcriptome analysis.
Development of MIEL platform.
We developed novel phenotypic screening platform, which interrogates the epigenetic landscape at single cell level using imaged-based machine learning. MIEL takes advantage of epigenetic marks such as histone methylation and acetylation, which are always present in eukaryotic nuclei and can be revealed by immunostaining. MIEL analyzes the immunolabeling patterns of epigenetic marks at the single-cell level -using conventional image analysis methods for segmentation of nuclei, feature extraction and previously described machine learning algorithms (26) (Fig. 2a, Supplementary Fig.   4a , b, and Methods).
Primarily, we utilized 4 histone modifications: H3K27me3 and H3K9me3, which are associated with condensed (closed) facultative and constitutive heterochromatin, respectively; H3K27ac, associated with transcriptionally active (open) areas of chromatin, especially at promoter and enhancer regions; and H3K4me1, associated with enhancers and other chromatin regions (27, 28) . To focus the learning algorithm on the intrinsic pattern of epigenetic marks, we discarded the intensity and nuclear morphology features and used only texture-associated features (e.g. Haralick's texture features (29) , threshold adjacency statistics, and radial features (30) ) for multivariate analysis.
Previous studies have successfully employed similar features for cell painting techniques combined with multivariate analyses to accurately classify subcellular localization of proteins (30) , cellular subpopulations(31), and drug mechanisms of action (26, (32) (33) (34) . We interpreted the observed patterns 6 as a 2D projection of the 3D topological distribution of a given epigenetic mark in the nucleus.
Although this representation degrades the spatial information, the resulting 2D textures, such as foci of high and low intensity, are visually apparent in the computer-enhanced images ( Supplementary   Fig. 4a ).
MIEL analysis provides signatures of cell fates.
We developed MIEL to distinguish between differentiated and undifferentiated TPCs, and to obtain a multiparametric signature of differentiated TPCs. To validate MIEL's ability to discriminate between different cellular states/fates involving major changes in chromatin organization (e.g., reprogramming
and differentiation), we analyzed 3 cell types: primary human fibroblasts isolated from 3 donors (WT-61, WT-101, WT-126), induced pluripotent stem cell (iPSC) lines derived from the fibroblasts, and neural progenitor cell (NPC) lines differentiated from the iPSCs, therefore providing genetically matching fibroblasts, iPSC and NPC cells (the cell lines were kindly provided by the Moutri group, UCSD). Cellular identities of the 3 cell types were verified by immunofluorescence (Fig. 2b ).
The 9 cell lines were immunostained for H3K4me1 and H3K9me3 marks, chosen based on major pattern alteration of these marks during differentiation (35, 36) . Note that immunostaining for H3K27ac and H3K27me3 marks produced a similar distance map ( Supplementary Fig. 5a ). Both pairs of epigenetic marks were used interchangeably for further analysis. We segmented images and extracted image features, as previously described (26) . Multivariate centroids were calculated for each cell population. Multi-dimension scaling (MDS) was employed to reduce 524 texture features into 2D and plotted to visualize the relative Euclidean distance between various cell populations (referred to as the "distance map"). Fibroblasts, iPSCs and NPCs each segregate to form 3 visually distinct territories (Fig. 2c ).
To determine whether it was possible to discriminate between individual cells with different fates, a Support Vector Machine (SVM) classifier was trained using fibroblasts, iPSCs, and NPCs derived from donor WT-61. This classifier accurately identified 79% of fibroblasts, 79% of iPSCs and 97% of NPCs (overall accuracy 85% Fig. 2d ; overall accuracy for H3K27ac and H3K27me3 based classification was 82% Supplementary Fig. 5b ). Similar results were obtained when the classifier was trained using cell lines from the other 2 donors. A classifier derived by pooling WT-61, WT-101, and
WT-126 cells correctly identified 89% of fibroblasts, 90% of iPSCs and 94% of NPCs (overall accuracy 91% Fig. 2e ; overall accuracy for H3K27ac and H3K27me3 based classification was 90% Supplementary Fig. 5c ). Furthermore, a direct pairwise classification distinguished different genetic backgrounds with 74% ( Supplementary Fig. 5d ). Additionally, MIEL analysis was able to discriminate between various primary hematopoietic cell types freshly isolated from mouse bone marrow suggesting that such analysis is not a cell culture artifact ( Supplementary Fig. 6 ).
These results suggest that MIEL can be used to distinguish between different differentiation states based on their single-cell epigenetic landscapes. Furthermore, we were able to derive multiparametric signatures for several cell types (e.g., fibroblasts, iPSCs, NPCs) that discriminate each cell type from the others.
MIEL determines signature of TPC differentiation.
To begin deriving the signature of GBM differentiation, we tested MIEL's ability to distinguish TPCs and differentiated glioma cells (DGCs), derived from the same primary human GBMs (6) . Three TPC/DGC pairs (kindly provided by the Bernstein group, MGH, Harvard) were derived in parallel from 3 genetically distinct GBM tumor samples (MGG4, MGG6, and MGG8) over a 3-month period using either serum-free FGF/EGF conditions for TPCs or 10% serum for DGCs (6) . MIEL analysis Next, we asked whether shorter serum treatment (compatible with the screening protocols)
would induce detectable epigenetic alterations. We treated 4 low-passage primary TPCs for 9 days with 10% serum and compared their epigenetic landscape to that of untreated cells and "terminally" theta: FBS-3d=-2.2±0.5; Fig. 3d and Supplementary Fig. 7c ).
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To test the accuracy of separating TPCs and DGCs at the single-cell level we generated an SVM classifier trained on texture features derived from a random subset of H3K27ac (Fig. 3e ).
These experiments demonstrate that MIEL is suitable to determine a signature of differentiated GBM cells across multiple genetic backgrounds. Furthermore, MIEL can detect serum-induced changes in GBM epigenetic pattern within several days to monitor the progress of TPC differentiation in a timeframe suitable for high content screening.
Validation of MIEL signature using global transcriptomic analysis.
Previous work indicated distinct features of GBM differentiation induced with BMP compared to serum (19) . Indeed, we observed distinct expression changes, including differences in expression of genes regulating chromatin organization and histone modifications (Supplementary Fig. 8 ), between serumand Bmp4-induced GBM differentiation. Therefore, we inquired whether MIEL approach could distinguish these differentiation modalities, in particular at the early time points.
We treated 4 genetically distinct GBM lines for 2 days with serum or BMP4 and conducted MIEL analysis using H3K9me3 and H3K4me1 marks. To visualize the changes induced by each treatment, we used polar plot normalization, as described above. Indeed, we observed that serum and BMP4 induce distinct epigenetic changes as detected by MIEL for each GBM line tested (Fig. 3f ).
Global gene expression profile represents a gold standard to define the cellular state (37).
Therefore, we asked whether the relative distances between distinct cellular states, for instance, untreated GBM cells, serum treated, and BMP treated GBM cells correlate using MIEL-based metrics and global gene expression-based metrics. We sequenced untreated and 3 days serum or Bmp4 treated GBM2 TPCs. All genes with FPKM>1 in at least one cell population were used to calculate the Euclidean distance matrix between all cell populations. FPKM-based distances were then correlated to image texture feature-based distances. The resulting Pearson correlation coefficient of R=0.93
suggests a high correlation between these 2 metrics (Fig. 3g, h ) and validates the robustness of MIEL approach for the analysis of GBM differentiation.
These experiments demonstrate that MILE is capable of distinguishing closely related GBM differentiation routes induced by serum or BMP. Critically, these results validate the robustness and accuracy of MIEL-based analysis of epigenetic patterns using conventional global gene expression approach.
MIEL prioritizes compounds based on serum/Bmp4 signature of GBM differentiation.
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To test whether MIEL can prioritize compounds based on serum/Bmp4 signature of GBM differentiation, we re-screened the Prestwick compound library (at lower concentration, 3 µM to minimize toxicity). GBM2 TPCs were plated on 384-well plates, treated for 3 days with Prestwick compounds fixed, and then immunostained for H3K27ac and H3K27me3. GBM2 cells treated with DMSO, serum, BMP4, or compound were compared within the same plate (to avoid imaging artifacts and normalization issues). To identify compounds inducing epigenetic changes reminiscent of serum/BMP4-induced differentiation, we conducted pairwise classification of DMSO-and either serum-or BMP4-treated cells. Because both serum and BMP4 induce TPC differentiation and reduce tumorigenicity we selected compounds that induced at least 50% of the cells to be classified as either serum-or BMP4-treated. We then calculated the Euclidean distance between these candidate compounds and serum/BMP4 treated cells -selecting compounds for which the distance to one or both treatments was less than the distance between DMSO and that treatment. This screen yielded 20 candidate compounds ( Supplementary Fig. 9a ), of which 15 belonged to 1 of the following 4 categories: Na/K-ATPase inhibitors of the digoxin family, molecules that disrupt microtubule formation or stability, topoisomerase inhibitors, and nucleotide analogues that disrupt DNA synthesis.
Of these 15 candidate compounds, we chose 2 top compounds from each of the 4 categories Indeed, no positive correlation was revealed ( Supplementary Fig. 10c ).
Next, we compared the levels of Sox2 expression under all treatment conditions to determine whether this metric is informative for identifying the drugs that best mimic serum/BMP4 treatment. We did not observe a positive correlation between Sox2 expression levels and the transcriptomic-based rankings (Fig. 4a) , suggesting that SOX2 level alone is insufficient to stratify the compounds.
To compare MIEL based signatures to the transcriptomic profile we first sought to get a comprehensive readout of the epigenetic landscape of treated cells. We therefore conducted MIEL analysis using an additional set of histone modifications including H3K9me3 and H3K4me1 marks.
We then ranked MIEL readouts of cells treated with the 8 drugs according to average Euclidean distance from serum-or Bmp4-treated cells (calculated using texture features derived from images of
Discussion
Cytotoxic drugs have had limited success treating GBM; therefore, we focused on the alternative approach -inducing GBM differentiation. We analyzed previously established biologicals such as serum and BMP4 known to induce GBM differentiation in culture (16) (17) (18) and established signatures of such differentiated GBM cells based on the pattern of epigenetic marks that could be applied across several genetic backgrounds. This is the first time that GBM differentiation signature suitable for high-throughput drug screening could be obtained. Indeed, the results of previous studies using bulk analysis of GBM (19) or single-cell sequencing (23) could not be readily applied for highthroughput screening. As a proof of principle, we analyzed Prestwick chemical library of 1200 approved drugs to validate MIEL's ability to select and prioritize small molecules, which mimic the effect of serum and BMP4 using global gene expression profiling. Surprisingly, we observed that the degree of reduction in endogenous SOX2 protein levels following drug treatment did not correlate with the degree of differentiation assessed by global gene expression. In contrast, the MIEL-based metrics did correlate with the degree of differentiation assessed by global gene expression.
Therefore, MIEL can be readily applied to screen large compound libraries using a reference signatures of GBM differentiation (e.g. serum or BMP4) to identify novel small molecules that mimic the effect of serum or BMP4 on GBM.
Accurately defining the identity of a cell is of fundamental importance to cell biology. Currently, this is done by assessing the presence or absence of a panel of experimentally verified lineagespecific markers. However, these markers require manual and arbitrary thresholding, which could be confusing and potentially contributes to multiple challenges of reproducibility in biomedical science (38, 39) . These concerns are alleviated by expression profiles that use hundreds of genes to assign a specific gene signature to a given cell type. However, at a single-cell level, expression profiling becomes stochastic, and is difficult to apply to high-throughput analysis in a cost-and time-effective manner. Phenotypic drug screening is an emerging technology that is revolutionizing drug discovery (26, 33, 40 
Materials and Methods.
Cell Culture: Monolayer cultures of patient-derived TPCs were propagated on Matrigel-coated plates in DMEM:F12 Neurobasal media (1:1; Gibco), 1% B27 supplement (Gibco), 10% BIT 9500 (StemCell Technologies), 1 mM glutamine, 20 ng/ml EGF (Chemicon), 20 ng/ml bFGF, 5 µg/ml insulin (Sigma), and 5 mM nicotinamide (Sigma). The medium was replaced every other day and the cells were enzymatically dissociated using Accutase prior to splitting. Fibroblasts, iPSCs, and iPSC-derived
NPCs were cultured as previously described (44, 45) .
Differentiation treatment: For TPC differentiation treatments cells were cultured in DMEM:F12
Neurobasal media (1:1), 1% B27 supplement, 10% BIT 9500, 1 mM glutamine supplemented with either Bmp4 (100ng/ml; R&D Systems) or FBS (10%).
Cell staining: Cells were rinsed with PBS and fixed in 4% paraformaldehyde in PBS for 10 min at room temperature. After blocking with PBSAT (2% BSA and 0.5% Triton X-100 in PBS) for 1 h at room temperature, the cells were incubated overnight at 4°C with primary antibodies diluted in PBSAT. The primary antibodies are listed in Table 2 , and the appropriate fluorochrome-conjugated secondary antibodies were used at 1:500 dilution. Nuclear co-staining was performed by incubating cells with Hoechst-33342 nuclear dye.
RNAseq and transcriptomic analysis:
Total RNA was isolated from GBM2 cells using the RNeasy Kit (Qiagen), 0.5 ug total RNA was used for isolation of mRNAs and library preparation. Library 
Microscopy and image analysis: Unless stated otherwise, for MIEL analysis cells were imaged on
an Opera QEHS high-content screening system (PerkinElmer) using ×40 water immersion objectives.
Images collected on the Opera were analyzed using Acapella 2.6 (PerkinElmer). At least 40 fields per well were acquired and at least 2 wells per population were used. Features of nuclear morphology, fluorescence intensity inter-channel co-localization, and texture features (Image moments, Haralick, Threshold Adjacency Statistics) were calculated using custom algorithms (scripts available from www.andrewslab.ca). A full list of the features used is available from the authors. Values for each cell were generated and exported to MATLAB for further analysis. For Sall2, Olig2, Brn2, Sox2, Oct4 and GFAP immunostaining, images were captured on an IC200-KIC (Vala Sciences) using a ×20 objective. Between 3 and 8 fields per well were acquired and analyzed using Acapella 2.6 (PerkinElmer). For all nuclear markers, average intensities in nucleus or fold change in average intensity compared to untreated cells are shown. Unless stated otherwise, at least 3 wells and a minimum of 300 cells for each condition were compared using unpaired two-tailed t-test was.
MDS:
The image features based profile for each cell population (eg, cell types, treatments) was However, as each cell line is divided by a different value, the distance vectors originating from two different lines represent the change in feature values induced by treatment, rather than the absolute feature values. Therefore, following MDS, the results are shown on a polar plot to indicate that the various treatments induce similar feature value changes in multiple lines rather than similar absolute values. As a result, direction and distance to the origin are comparable between lines while distances directly between points are not.
SVM classification: SVM classification was conducted as previously described (26) . Cell-level data in all populations (minimum 400 cells per population) together were normalized to z-scores and a subset of cells from each of the populations being classified was randomly chosen as the training set (subset size is at least 100× the number of populations being classified). The training set was used to train a SVM classifier (MATLAB function 'svmtrain'). The remaining cells (test set) were then classified using the SVM-derived classifier to assess the accuracy of classification (MATLAB function 'svmclassify'). Here, the accuracy of all pairwise classifications is given as the average accuracy calculated for each of the populations. To utilize classification to determine the similarity of multiple cell populations, we classified known populations (such as different treatments or cell fates) to generate known 'bins' and then used the same classifiers on the unknown population to categorize each cell.
Prestwick Chemical Library screen using H3K27me3 and H3K27ac: GBM2 cells were plated at 2000 cells/well and exposed to Prestwick compounds (3 µM) for 3 days in 384-well optical bottom assay plates (PerkinElmer). Cells were then fixed and stained with rabbit polyclonal anti-H3K27ac
and mouse monoclonal anti-H3K27me3 (Table 2) antibodies followed by AlexaFluor-488-or AlexaFluor-555-conjugated secondary antibodies. The positive control treatments were BMP4 (100 ng/ml) and serum (10%), negative controls were DMSO (0.1%). DNA was counterstained with Hoechst. Images were acquired using the Perkin Elmer Opera® QEHS. MIEL analysis was conducted as described above. The robust Z′-score (RZ') is based on the Z′-score described in (32) 
Correlation of transcriptomic and image-based profiles:
Euclidean distance between untreated, serum or Bmp4 treated GBM2 cells (triplicates for each) was calculated using either transcriptomic data (FPKM) or texture features. Pearson's correlation coefficient (R) was transformed to a t-value using the formula (t = R × SQRT(N-2)/SQRT (1-R2) where N is the number of samples, and R is
Pearson correlation coefficient, and the p-value was calculated using Excel tdist(t) function. For compound prioritization, the Euclidean distance between compound treated and serum or Bmp4 treated GBM2 cells was calculated based on either transcriptomic data (FPKM) or image features.
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